Statin therapy in patients with high and very high cardiovascular risk: an optimal approach
https://doi.org/10.15829//1728-8800-2020-2696
Abstract
This article discusses the problems of adequate therapy for dys-lipidemia in patients with high and very high cardiovascular risk in clinical practice. Updated Russian and European guidelines for the treatment of dyslipidemia pick out five categories of cardiovascular risk and clarify goals of prevention and treatment of atherosclerosis. The data of most significant clinical studies on rosuvastatin, highlighting its high lipid-lowering efficacy, the effect on the progression of atherosclerosis and the prognosis in patients with cardiovascular disease, are presented.
About the Authors
E. V. Sayutina
I.M. Sechenov First Moscow State Medical University; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
M. M. Shamuilova
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Moscow
L. I. Butorova
I.M. Sechenov First Moscow State Medical University; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
E. M. Tuayeva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. L. Vertkin
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
References
1. Federal State Statistics Service (Rosstat). Healthcare in Russia 2017 Statistical collection. М., 2017 170 с. (In Russ). ISBN: 978-5-89476-448-1.
2. Sergienko IV, Ensheles AA, Kukharchuk VV. Dislipidemia, atherosclerosis and ischemic heart disease: modern aspects of pathogenesis, diagnosis and treatment. 3 ed., transcript and supplement M, 2018. (In Russ). ISBN: 9785-90363-088-2.
3. Chazova IE, Gernakova YV, Oschepkova EV, et al. Prevalence of risk factors for cardiovascular diseases in the Russian population of hypertension patients. Kardiologiia. 2014;54(10):4-12. (In Russ). doi: 10.18565/cardio.2014.10.4-12.
4. Meshkov AN, Ershova AI, Deev AI, et al. Distribution of lipid spectrum indicators in men and women of working age in the Russian Federation: results of the ESSE-RF study for 20122014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7 (In Russ.) doi:10.15829/1728-8800-2017-4-62-67.
5. Boitsov SA, Susekov AV, Aronov DM, et al. Topical issues of statin therapy in clinical practice. Expert council meeting. Atherosclerosis and dyslipidemia. 2011;1:65-6. (In Russ.)
6. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;00:1-78. doi: 10.1093/eurheartj/ehz455.
7. Atherosclerosis and dyslipidemia. Diagnostics and correction of lipid metabolism disorders to prevent and treat atherosclerosis. Russian Recommendations, VII revision. 2020; 1(38):7-42. (In Russ). doi: 10.34687/2219-8202.JAD.2020.01.0002.
8. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials. Lancet. 2010;376:1670-81. doi:10.1016/S0140-6736(10)61350-5.
9. Sergienko IV. History of appearance of statins. Atherosclerosis and dyslipidemia. 2011;1:57-66. (In Russ.)
10. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168-209. doi: 10.1016/j.jacc.2018.11.002.
11. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97 doi:10.1056/NEJMoa1410489.
12. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485-94. doi:10.1016/j.jacc.2014.02.615.
13. Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardio vascular outcomes after acute coronary syndrome. New Engl J Med. 2018;379(22):2097-107 doi:10.1056/NEJMoa1801174.
14. Luvai A, Mbagaya W, Hall AS, et al. Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease. Clin Med Insights: Cardiol. 2012;6:17-33. doi:10.4137/CMC.S4324.
15. Jones PH, Davidson MH, Stein EA, et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92(2):152-60. doi:10.1016/s0002-9149(03)00530-7.
16. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY I) study. Am Heart J. 2004;147:705-12. doi:10.1016/j.ahj.2003.10.004.
17. 17 Izzat L. The MERCURY II trial: benefits of rosuvastatin. Br J Diabetes Vasc Dis. 2006;6(4): 171-6. doi: 10.1177/1474651406 0060040501.
18. Berne C, Siewert-Delle A, and the URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005;4:7 doi:10.1186/1475-2840-4-7.
19. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther. 2007;5(2):177-93. doi:10.1586/14779072.5.2.177
20. Crouse JR, Raichlen JS, Riley WA. Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis The METEOR Trial. JAMA. 2007;297:1344-53. doi:10.1001/jama.297.12.1344.
21. Nissen S, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity stain therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295(13): 1556-65. doi:10.1001/jama.295.13.jpc60002.
22. Nicholls SJ, Borgman M, Nissen SE, et al. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin). Curr Med Res Opin. 2011;27:1119-29. doi:10.1185/03007995.2011.570746.
23. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/l) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol. 2007; 100:1245-8. doi:10.1016/j.amjcard.200705.044.
24. Binbrek AS, Elis A, Al-Zaibag M, et al. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha Study). Curr Ther Res Clin Exp. 2006;67:21-43. doi: 10.1016/j.curtheres.2006.02.005.
25. Clearfield MB, Amerena J, Bassand J, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia — Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006;7:35. doi:10.1186/1745-6215-7-35.
26. Danchin N, Chadarevian R, Gayet J-L, et al. Compared with atorvastatin at a dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of <1,00 g/l in high cardiovascular risk patients (ARIANE study). Ann Cardiol Angiol (Paris). 2007;56:82-7 doi:10.1016/j.ancard.200701.003.
27. 27 Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55:1266-73. doi:10.1016/j.jacc.2010.01.020.
28. Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-61. doi:10.1056/NEJMoa0706201.
29. Leiter LA, Rosenson RS, Stein E, et al. POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007; 194(2):e154-64. doi:10.1016/j.atherosclerosis.2006.12.00.
30. Faergeman O, Hill L, Windler E, et al. ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-28. doi:10.1159/000127442.
31. Ray KK, Cannon CP, McCabe CH, et al. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin 41. in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46(8):1405-10. doi:10.1016/j.jacc.2005.03.077.
32. Lablanche JM, Danchin N, Farnier M, et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch Cardiovasc Dis. 2008;101:399-406. doi: 10.1016/j.acvd.2008.05.010.
33. Garcfa-Rodrfguez LA, Masso-Gonzalez EL, Wallander M, et al. The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care. Pharmacoepidemiol Drug Saf. 2008;17:943-52. doi:10.1002/pds.1603.
34. Perez-Calahorra S, Laclaustra M, Marco-Benedi V, et al. Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids Health Dis. 2019;18:216. doi:10.1186/s12944-019-1153-x.
35. De Backer G, Jankowskib P, Kotseva K, et al. EUROASPIRE V collaborators. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135-46. doi:10.1016/j.atherosclerosis.2019.03.014.
36. Ezhov MV, Bliznyuk SA, Alekseeva IA, Vygodin VA. Prevalence of hypercholesterolemia and application of statins in outpatient practice in the Russian Federation. AISTERG. Atherosclerosis and Dislipidemia study. Journal of the National Society for the Study of Atherosclerosis. 2017;4(29):5-17 (In Russ.)
37. 37 Akhmedjanov NM, Nebieridze DV, Safaryan AS, et al. Hypolipidemic Therapy in Outpatient Practice (according to ARGO-2 study). Rational Pharmacotherapy in Cardiology. 2016; 12(2): 147-53. (In Russ.) doi:10.20996/1819-6446-2016-12-2-147-153.
38. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol. 2004;94(7):882-8. doi: 10.1016/j. amjcard.2004.06.049.
39. Savarese G, Musella F, Volpeet M, et al. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Int J Cardiol. 2013;167(6):2482-9. doi:10.1016/j.ijcard.2012.05.010.
40. Yun KH, Shin IS, Shin SN, et al. Effect of previous statin therapy in patients with acute coronary syndrome and percutaneous coronary intervention. Korean. Circ J. 2011;41(8):458-63. doi:10.4070/kcj.2011.41.8.458.
41. Wiggins BS, Saseen JJ, Page RL, et al. American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology. Recommendations for management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016;134(21):e468-95. doi:10.1161/CIR.0000000000000456.
42. Mishchenko MA, Kononova SV. Analysis of factors influencing adherence to hypolipidemic therapy. Medical almanac. 2014; 1(31 ):95-8. (In Russ.)
43. Masana L. Pitavastatin — from clinical trials to clinical practice. Atheroscler Suppl. 2010; 11 (3): 15-22. doi: 10.1016/s1567-5688(10)71065-5.
Review
For citations:
Sayutina E.V., Shamuilova M.M., Butorova L.I., Tuayeva E.M., Vertkin A.L. Statin therapy in patients with high and very high cardiovascular risk: an optimal approach. Cardiovascular Therapy and Prevention. 2020;19(5):2696. (In Russ.) https://doi.org/10.15829//1728-8800-2020-2696
Views:
823
Email this article 
